Pulmonary Vascular Disease
Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study

https://doi.org/10.1378/chest.1992777Get rights and content

Section snippets

Abstract

SESSION TITLE: Pulmonary Hypertension

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 28, 2014 at 02:45 PM - 04:15 PM

PURPOSE: Combining drugs that target different pathophysiological pathways is a recommended treatment strategy in PAH [1]. COMPASS-2 investigated the safety and efficacy of adding bosentan in PAH patients already receiving sildenafil.

METHODS: In this double-blind, placebo-controlled, Phase IV, add-on, event-driven study, patients with symptomatic PAH

References (0)

Cited by (0)

View full text